Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-FAP-ICG
- Development stage
- Preclinical
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-FAP-ICG is a novel multimodal radiopharmaceutical probe integrating positron emission tomography (PET) and near-infrared II (NIR-II) fluorescence imaging. It consists of a fibroblast activation protein (FAP)-targeted peptide conjugated with indocyanine green (ICG) and labeled with gallium-68 (68Ga). The agent is designed for the preoperative localization and real-time intraoperative navigation/guided resection of lung cancer by targeting cancer-associated fibroblasts (CAFs) that overexpress FAP in the tumor stroma.
- Other names
- FAP-ICG
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 68Ga-FAP-ICG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-FAP-ICG.